This Duke Consortia for HIV/AIDS Vaccine Development (CHAVD) funded in 2019 will apply state-of-the-art technologies and immunologic tools to focus on iterative, rational vaccine design that within 7 years will lead to a successful final vaccine design. There were two consortiums funded, one at Duke University and one at Scripps Research Institute.

Duke Human Vaccine Institute Wins Contract to Produce Pan-Coronavirus Vaccine

The Duke Human Vaccine Institute has received a federal contract to manufacture a pan-coronavirus vaccine candidate that can be tested in a phase 1 clinical trial.
 
Awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), the base period of the contract provides $11.2 million to support the program; additional provisions in the contract could increase the total funding up to $21.5 million if all option periods are exercised.